Schedule 13G Paul Maddon December 31, 2006
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
Under
the
Securities Exchange Act of 1934
(Amendment
No. 6)*
Progenics
Pharmaceuticals, Inc.
------------------------------------------------------------------------------------------------------------
(Name
of
Issuer)
Common
Stock, par value $0.0013 per share
------------------------------------------------------------------------------------------------------------
(Title
of
Class of Securities)
743187106
----------------------------------
(CUSIP
Number)
December
31, 2006
------------------------------------------------------------------------------------------------------------
(Date
of
Event Which Requires Filing of this Statement)
Check
the
appropriate box to designate the rule pursuant to which this Schedule is
filed:
[_]
Rule
13d-1(b)
[
] Rule
13d-1(c)
[X]
Rule
13d-1(d)
*The
remainder of this cover page shall be filled out for a reporting person’s
initial filing on this form with respect to the subject class of securities,
and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed
to
be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the
Notes).
---------------------------------
CUSIP
NO.
743187106
---------------------------------
---------------------------------------------------------------------------------------------------------------------------------
NAME
OF
REPORTING PERSON
1. I.R.S.
IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Paul
J.
Maddon, M.D., Ph.D.
---------------------------------------------------------------------------------------------------------------------------------
CHECK
THE
APPROPRIATE BOX IF A MEMBER OF A GROUP
2.(a)
[_]
(b) [_]
---------------------------------------------------------------------------------------------------------------------------------
SEC
USE
ONLY
3.
---------------------------------------------------------------------------------------------------------------------------------
CITIZENSHIP
OR PLACE OF ORGANIZATION
4.
United
States of America
---------------------------------------------------------------------------------------------------------------------------------
SOLE
VOTING POWER
5.
NUMBER
OF
1,791,863
SHARES --------------------------------------------------------------------------------------
SHARED
VOTING POWER
BENEFICIALLY 6.
OWNED
BY None
--------------------------------------------------------------------------------------
EACH SOLE
DISPOSITIVE POWER
7.
REPORTING
1,791,863
PERSON --------------------------------------------------------------------------------------
SHARED
DISPOSITIVE POWER
WITH: 8.
None
---------------------------------------------------------------------------------------------------------------------------------
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9.
1,791,863
---------------------------------------------------------------------------------------------------------------------------------
CHECK
IF
THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
10.[_]
---------------------------------------------------------------------------------------------------------------------------------
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11.
6.5%
---------------------------------------------------------------------------------------------------------------------------------
TYPE
OF
REPORTING PERSON
12.
IN
---------------------------------------------------------------------------------------------------------------------------------
Item
1.
(a) Name
of
Issuer:
Progenics
Pharmaceuticals, Inc.
(b) Address
of Issuer’s Principal Executive Offices:
777
Old
Saw Mill River Road
Tarrytown,
NY 10591
Item
2.
(a) Name
of
Person Filing:
Paul
J.
Maddon, M.D., Ph.D.
(b) Address
of Principal Business Office or, if none, Residence:
777
Old
Saw Mill River Road
Tarrytown,
NY 10591
(c) Citizenship:
United
States of America
(d) Title
of
Class of Securities:
Common
Stock, par value $0.0013 per share
(e) CUSIP
Number:
743187106
Item
3.
|
If
this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or
(c),
check whether the person filing is
a:
|
(a) Amount
Beneficially Owned:
1,791,863
shares, which includes 639,987 shares, 1,151,876 shares that may be acquired
upon exercise of certain options held by reporting person and 1,000 shares
held
by reporting person's spouse (the beneficial ownership of which the reporting
person disclaims).
Excludes
90,229 shares held by a trust, of which the reporting person’s spouse is the
beneficiary; neither the reporting person nor his spouse has investment control
over such trust.
(b) Percent
of class:
6.5%
(c) Number
of
shares as to which the person has:
(i) Sole
power to vote or to direct the vote
1,791,863
(ii) Shared
power to vote or to direct the vote
None
(iii) Sole
power to dispose or to direct the disposition of
1,791,863
(iv) Shared
power to dispose or to direct the disposition of
None
Item
5.
|
Ownership
of Five Percent or Less of a Class.
|
Item
6.
|
Ownership
of More than Five Percent on Behalf of Another
Person.
|
Item
7.
|
Identification
and Classification of the Subsidiary Which Acquired the Security
Being
Reported on by the Parent Holding
Company.
|
Item
8.
|
Identification
and Classification of Members of the
Group.
|
Item
9.
|
Notice
of Dissolution of Group.
|
N/A
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that
the information set forth in this statement is true, complete and
correct.
February
14, 2007
/s/
Paul
J. Maddon, M.D., Ph.D.
Paul
J.
Maddon, M.D., Ph.D.